Lantheus Holdings, Inc. clinical trials

The registry lists 77 studies whose lead sponsor is Lantheus Holdings, Inc. or one of 7 companies grouped under it. 4 are recruiting or about to start. Per ClinicalTrials.gov, last updated Oct 23, 2026.

Studies

Recruiting first, then most recently updated. Showing 50 of 77. Browse all 77 →

• [18F]PI-2620 Phase 3 Histopathological StudyRecruitingNCT05641688Phase 3

  Sponsor listed in the registry: Lantheus Biosciences Ltd. · First submitted before Lantheus Biosciences Ltd. became part of Lantheus Holdings, Inc.

• Dose Optimization and Diagnostic Performance in Prostate Cancer (SPARROW [Staging Prostate Cancer With Advanced RM2 Radiotracer Oncologic Workup])RecruitingNCT07831824Phase 2/3

  Sponsor listed in the registry: Lantheus Medical Imaging

• Lu-TARGO (177Lu-TARGeted Osteosarcoma Therapy)RecruitingNCT07357519Phase 1/2

  Sponsor listed in the registry: Lantheus Medical Imaging

• 64Cu-LNTH-1363S in Patients With Sarcoma or Gastrointestinal Tract CancerRecruitingNCT06298916Phase 1/2

  Sponsor listed in the registry: Lantheus Medical Imaging

• Test-retest Study With [18F]FBB in Cardiac AmyloidosisCompletedNCT06790394Phase 1

  Sponsor listed in the registry: Lantheus Germany GmbH · First submitted before Lantheus Germany GmbH became part of Lantheus Holdings, Inc.

• Impact of FBB PET Amyloid Imaging in Change of Diagnosis in Patients With ADCompletedNCT02681172Phase 4

  Sponsor listed in the registry: Lantheus Biosciences Ltd. · First submitted before Lantheus Biosciences Ltd. became part of Lantheus Holdings, Inc.

• An Observational Registry Assessing the Impact of PYLARIFY® (Piflufolastat F18) PET in Patients With Prostate CancerActive, not recruitingNCT05712473

  Sponsor listed in the registry: Lantheus Medical Imaging

• Efficacy of [18F]Florbetaben PET for Diagnosis of Cardiac AL AmyloidosisCompletedNCT05184088Phase 3

  Sponsor listed in the registry: Lantheus Germany GmbH · First submitted before Lantheus Germany GmbH became part of Lantheus Holdings, Inc.

• Piflufolastat F 18 PET/CT in Patients With Suspected, or at High Risk for Metastatic ccRCCWithdrawnNCT07084909Phase 2/3

  Sponsor listed in the registry: Lantheus Medical Imaging

• I-131-1095 Radioligand Plus Enzalutamide vs Enzalutamide for mCRPC That Progressed During Abiraterone (ARROW).CompletedNCT03939689Phase 2

  Sponsor listed in the registry: Progenics Pharmaceuticals, Inc. · First submitted before Progenics Pharmaceuticals, Inc. became part of Lantheus Holdings, Inc.

• PYLARIFY® PET/CT or PET/MRI in Men With Favorable Intermediate Risk (FIR) Prostate CancerActive, not recruitingNCT06074510Phase 4

  Sponsor listed in the registry: Lantheus Medical Imaging

• Test-retest Study With [18F]PI-2620 in PSP-RS and NDCCompletedNCT05187546Phase 1

  Sponsor listed in the registry: Life Molecular Imaging GmbH · First submitted before Life Molecular Imaging GmbH became part of Lantheus Holdings, Inc.

• Evaluation of Imaging Characteristics of [18F]PI-2620 PET in AD and PSP Patients Using High and Low Specific ActivityCompletedNCT04715750Phase 1

  Sponsor listed in the registry: Life Molecular Imaging GmbH · First submitted before Life Molecular Imaging GmbH became part of Lantheus Holdings, Inc.

• Expanded Access Treatment with [Lu-177]-PNT2002 for Adult Patients with Prostate-Specific Membrane Antigen (PSMA)-Positive Metastatic Castration-Resistant Prostate Cancer (mCRPC)Temporarily not availableNCT06033001

  Sponsor listed in the registry: Lantheus Medical Imaging

• Imaging [18F]PI-2620 and [18F]Florbetaben in Military Service Members With Blast Related Mild Traumatic Brain InjuryTerminatedNCT05337774Phase 1

  Sponsor listed in the registry: Life Molecular Imaging SA · First submitted before Life Molecular Imaging SA became part of Lantheus Holdings, Inc.

• Study of 18F-DCFPyL PET/CT Imaging in Patients With Prostate CancerCompletedNCT02981368Phase 2/3

  Sponsor listed in the registry: Progenics Pharmaceuticals, Inc. · First submitted before Progenics Pharmaceuticals, Inc. became part of Lantheus Holdings, Inc.

• Study of 18F-DCFPyL PET/CT Imaging in Patients With Suspected Recurrence of Prostate CancerCompletedNCT03739684Phase 3

  Sponsor listed in the registry: Progenics Pharmaceuticals, Inc. · First submitted before Progenics Pharmaceuticals, Inc. became part of Lantheus Holdings, Inc.

• A Study of Stress Echocardiography in Post-Menopausal Women at Risk for Coronary DiseaseCompletedNCT00162370Phase 4

  Sponsor listed in the registry: Lantheus Medical Imaging

• DEF-315 Better Accuracy in Ejection Fraction (EF) Assessment With DEFINITYCompletedNCT03719612Phase 3

  Sponsor listed in the registry: Lantheus Medical Imaging

• DEF-314 Better Accuracy in Ejection Fraction (EF) Assessment With DEFINITYCompletedNCT03571672Phase 3

  Sponsor listed in the registry: Lantheus Medical Imaging

• A Study of Commercial DEFINITY® to Monitor the Effects of the Heart's Pulmonary Artery PressureCompletedNCT00918866Phase 4

  Sponsor listed in the registry: Lantheus Medical Imaging

• A Prospective, Phase IV, Surveillance Registry Study to Evaluate the Safety of DEFINITY® in Clinical PracticeCompletedNCT00625365Phase 4

  Sponsor listed in the registry: Lantheus Medical Imaging

• A Phase 3 Multi-center Study to Assess PET Imaging of Flurpiridaz F 18 Injection in Patients With CAD.CompletedNCT01347710Phase 3

  Sponsor listed in the registry: Lantheus Medical Imaging

• A Phase 1 Trial to Determine Dosimetry, Biodistribution and Safety of LMI 1195-101 in Healthy Subjects and Patients With Heart FailureCompletedNCT00891241Phase 1

  Sponsor listed in the registry: Lantheus Medical Imaging

• Study of [3H] BMS747158 in Healthy Male SubjectsCompletedNCT00930631Phase 1

  Sponsor listed in the registry: Lantheus Medical Imaging

• Retrospective Safety Study to Compare Mortality in Intensive Care Unite (ICU) Patients Undergoing Echocardiography With or Without DEFINITY®CompletedNCT01299649

  Sponsor listed in the registry: Lantheus Medical Imaging

• A Phase I Study in Healthy Volunteers to Assess Dosimetry and Safety Following Injection of BMS747158 at StressCompletedNCT00707538Phase 1

  Sponsor listed in the registry: Lantheus Medical Imaging

• A Phase I Study in Healthy Volunteers to Assess Safety of BMS747158CompletedNCT00707499Phase 1

  Sponsor listed in the registry: Lantheus Medical Imaging

• A Study Evaluating Ultratrace Iobenguane I131 in Patients With Malignant Relapsed/Refractory Pheochromocytoma/ParagangliomaStatus unknownNCT00874614Phase 2

  Sponsor listed in the registry: Molecular Insight Pharmaceuticals, Inc. · First submitted before Molecular Insight Pharmaceuticals, Inc. became part of Lantheus Holdings, Inc.

• A Study to Evaluate the Use and Safety of CARDIOLITE® in Pediatric Patients With Kawasaki DiseaseCompletedNCT00162032Phase 3

  Sponsor listed in the registry: Lantheus Medical Imaging

• Study to Evaluate 99mTc-MIP-1404 SPECT/CT Imaging in Men With Biopsy Proven Low-Grade Prostate CancerCompletedNCT02615067Phase 3

  Sponsor listed in the registry: Molecular Insight Pharmaceuticals, Inc. · First submitted before Molecular Insight Pharmaceuticals, Inc. became part of Lantheus Holdings, Inc.

• Expanded Access Program of Ultratrace Iobenguane I131 for Malignant Relapsed/Refractory Pheochromocytoma/ParagangliomaApproved for marketingNCT02961491

  Sponsor listed in the registry: Molecular Insight Pharmaceuticals, Inc. · First submitted before Molecular Insight Pharmaceuticals, Inc. became part of Lantheus Holdings, Inc.

• N2007-01: Ultratrace™ Iobenguane I 131 in Patients With Relapsed/Refractory High-Risk NeuroblastomaCompletedNCT00659984Phase 2

  Sponsor listed in the registry: Molecular Insight Pharmaceuticals, Inc. · First submitted before Molecular Insight Pharmaceuticals, Inc. became part of Lantheus Holdings, Inc.

• A Study of PSMA ADC in Subjects With Metastatic Castration-resistant Prostate Cancer (mCRPC)CompletedNCT01695044Phase 2

  Sponsor listed in the registry: Progenics Pharmaceuticals, Inc. · First submitted before Progenics Pharmaceuticals, Inc. became part of Lantheus Holdings, Inc.

• An Open-label Extension Study of PSMA ADC 2301 in mCRPCCompletedNCT02020135Phase 2

  Sponsor listed in the registry: Progenics Pharmaceuticals, Inc. · First submitted before Progenics Pharmaceuticals, Inc. became part of Lantheus Holdings, Inc.

• PET/CT Imaging Study of the Safety and Diagnostic Performance of [68Ga]RM2 in Patients With Primary Prostate CancerTerminatedNCT02483884Phase 1/2

  Sponsor listed in the registry: Life Molecular Imaging SA · First submitted before Life Molecular Imaging SA became part of Lantheus Holdings, Inc.

• A Phase 2 Study With MIP-1404 in Men With High-Risk PC Scheduled for RP and EPLND Compared to HistopathologyCompletedNCT01667536Phase 2

  Sponsor listed in the registry: Molecular Insight Pharmaceuticals, Inc. · First submitted before Molecular Insight Pharmaceuticals, Inc. became part of Lantheus Holdings, Inc.

• PET Imaging of Intracranial Cancers With 18F-FSPGTerminatedNCT02370563Phase 1

  Sponsor listed in the registry: Life Molecular Imaging SA · First submitted before Life Molecular Imaging SA became part of Lantheus Holdings, Inc.

• Phase 1 Study of Iobenguane (MIBG) I 131 in Patients With Malignant Pheochromocytoma/ParagangliomaCompletedNCT00458952Phase 1/2

  Sponsor listed in the registry: Molecular Insight Pharmaceuticals, Inc. · First submitted before Molecular Insight Pharmaceuticals, Inc. became part of Lantheus Holdings, Inc.

• Phase III Study of Florbetaben (BAY94-9172) PET Imaging for Detection/Exclusion of Cerebral β-amyloid Compared to HistopathologyCompletedNCT01020838Phase 3

  Sponsor listed in the registry: Life Molecular Imaging SA · First submitted before Life Molecular Imaging SA became part of Lantheus Holdings, Inc.

• Safety and Efficacy Iodofiltic Acid I 123 in the Treatment of Acute Coronary SyndromeCompletedNCT00514501Phase 2

  Sponsor listed in the registry: Molecular Insight Pharmaceuticals, Inc. · First submitted before Molecular Insight Pharmaceuticals, Inc. became part of Lantheus Holdings, Inc.

• Efficacy and Safety of Ultratrace™ Iobenguane I 131 in NeuroblastomaWithdrawnNCT00992173Phase 2

  Sponsor listed in the registry: Molecular Insight Pharmaceuticals, Inc. · First submitted before Molecular Insight Pharmaceuticals, Inc. became part of Lantheus Holdings, Inc.

• Study to Evaluate the Efficacy and Safety of 90Y-SMT487 in Subjects With Symptomatic Malignant Carcinoid TumorsWithdrawnNCT00696930Phase 2

  Sponsor listed in the registry: Molecular Insight Pharmaceuticals, Inc. · First submitted before Molecular Insight Pharmaceuticals, Inc. became part of Lantheus Holdings, Inc.

• 99mTc-MIP-1404 for Imaging Prostate Cancer: Phase I Clinical Study to Assess the Image Quality of a Simplified Kit Formulation Compared to a Multi-step Preparation of 99mTc-MIP-1404CompletedNCT01654874Phase 1

  Sponsor listed in the registry: Molecular Insight Pharmaceuticals, Inc. · First submitted before Molecular Insight Pharmaceuticals, Inc. became part of Lantheus Holdings, Inc.

• Pilot Study of 99mTc-MIP-1404 SPECT/CT Imaging in Men With Prostate Cancer Undergoing Prostatectomy and/or Pelvic Lymph Node DissectionCompletedNCT01572701Phase 1

  Sponsor listed in the registry: Molecular Insight Pharmaceuticals, Inc. · First submitted before Molecular Insight Pharmaceuticals, Inc. became part of Lantheus Holdings, Inc.

• A Phase 1 Pilot Study of 99mTc-MIP-1404 SPECT/CT Imaging to Histology in Men With Prostate CancerCompletedNCT01615406Phase 1

  Sponsor listed in the registry: Molecular Insight Pharmaceuticals, Inc. · First submitted before Molecular Insight Pharmaceuticals, Inc. became part of Lantheus Holdings, Inc.

• A Pilot Study of 123I-MIP-1072 SPECT/CT Imaging With Optional Compact Gamma Camera Probe Imaging in Men With Prostate Cancer Undergoing ProstatectomyWithdrawnNCT01279785

  Sponsor listed in the registry: Molecular Insight Pharmaceuticals, Inc. · First submitted before Molecular Insight Pharmaceuticals, Inc. became part of Lantheus Holdings, Inc.

• A Study of 99mTc-MIP-1404 and 99mTc-MIP-1405 in Patients With Metastatic Prostate Adenocarcinoma and Healthy VolunteersCompletedNCT01261754Phase 1

  Sponsor listed in the registry: Molecular Insight Pharmaceuticals, Inc. · First submitted before Molecular Insight Pharmaceuticals, Inc. became part of Lantheus Holdings, Inc.

• Development of 1-Day Rest/Stress Cardiac PET Perfusion Imaging Protocol of BMS747158CompletedNCT00849108Phase 2

  Sponsor listed in the registry: Lantheus Medical Imaging

• Trial to Determine Imaging Parameters of LMI1195 in Heart Failure Patients at Low and High Risk of Defibrillator FiringWithdrawnNCT01085175Phase 2

  Sponsor listed in the registry: Lantheus Medical Imaging